Country websites

Strategy

Our Strategy

At Fresenius Medical Care, we have a long history of innovation and growth. Over the past years, the environment in which we operate has changed meaningfully. With our turnaround and transformation plan, we have taken decisive actions and progressed, successfully reshaping our operating model and streamlining our organization. 

Through our vertical integration, scope, and scale, we serve around 299,000 dialysis patients worldwide and provide products in around 150 countries.

With FME Reignite, we have set a strong ambition for the future. We strive to deliver industry-leading outcomes, generate margins with above-market growth, and drive value creation. This is reflected in our three business segments: Care Delivery, Care Enablement, and Value-Based Care, a powerful cycle of care and innovation that delivers greater value to our patients, partners, and company.


In Care Delivery, we are solidifying  our position as one of the world’s leading provider of kidney care services.

 
In Care Enablement, we are winning as the global leader in kidney replacement technology.


With Value-Based Care, we are taking responsibility for the integrated healthcare of our patients.  

Our DNA is advancing kidney care.

FME Reignite is founded on three strategic priorities:

  • Reignite the core: Strengthen core operations
  • Reignite growth and innovation: Drive profitable growth and innovation
  • Reignite our culture: Develop together and strengthen our culture

Watch what we are doing to take Fresenius Medical Care to the next level.

Our Strategic Priorities

As we take our company to the next level, our strategy is clear: We lead kidney care through exceptional patient care and innovation. Our evolved strategy, FME Reignite, is founded on three strategic priorities with one overall goal: create value for all our stakeholders, including patients, customers, employees, partners, and shareholders.

 

Reigniting the core means being operationally excellent in everything we do. It’s about driving high-quality care consistently and worldwide. It requires us to standardize and improve processes to enable growth. And it will result in focused investments to drive improved outcomes.

 

Reigniting growth and innovation means we want to lead the market by further enhancing clinical outcomes and patient safety. We will innovate to differentiate and grow profitably by building a global product platform that allows for focused enhancement of treatment pathways and quality. It’s about setting a new standard of care in the U.S. with high-volume hemodiafiltration (HVHDF) and leveraging our product leadership to further expand market share and drive volume growth. It’s about driving an AI-powered transformation in patient care, research, and operations. And it’s about continuing to grow purposefully internationally.

 

Reigniting our culture means we are people taking care of people, and it’s vital that we also take care of ourselves. We will focus on further developing our people to attract, retain, and engage the very best talent. We want this to be the place where everyone else wants to be; we want to be the employer of choice. It’s everyone’s job to help make this a reality.

Related content